• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经导管植入房间隔分流装置以降低心力衰竭患者的左心房压力

Transcatheter Implantation of Interatrial Shunt Devices to Lower Left Atrial Pressure in Heart Failure.

作者信息

Jørgensen Troels Højsgaard, Søndergaard Lars

机构信息

Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

出版信息

Int J Heart Fail. 2022 Jan 19;4(1):12-23. doi: 10.36628/ijhf.2021.0038. eCollection 2022 Jan.

DOI:10.36628/ijhf.2021.0038
PMID:36262198
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9383341/
Abstract

Patients with heart failure with preserved ejection fraction (HFpEF) constitutes a considerable sized population like that of subjects with heart failure with reduced ejection fraction. The symptoms include exercise induced dyspnoea and fatigue besides an increased mortality rate when compared to the general population. There is limited evidence of benefit from pharmacological therapy. A main pathophysiological mechanism is a left ventricular filling pressure that might be near to normal during resting conditions but increases during exercise leading to pulmonary congestion. Based on observations like the apparent lesser symptomatology in patients with combined mitral valve stenosis and atrial septal defect (Lutembacher syndrome) when compared to patients with isolated mitral valve stenosis, several Inter-Atrial Shunt Devices (IASD) have been developed with the intent to unload the pressure in the left atrium by creating a shunt into the right atrium. Smaller studies have found that the IASDs reduce the left ventricular filling pressure during exercise and increase the functional status of patients both subjectively and objectively with reported low rates of complications. These devices are undergoing further investigations and might prove to be a new paradigm in the treatment of patients with HFpEF.

摘要

射血分数保留的心力衰竭(HFpEF)患者构成了一个规模可观的群体,与射血分数降低的心力衰竭患者群体相当。其症状包括运动诱发的呼吸困难和疲劳,而且与普通人群相比死亡率更高。药物治疗的获益证据有限。一个主要的病理生理机制是左心室充盈压,其在静息状态下可能接近正常,但在运动时会升高,导致肺淤血。基于诸如二尖瓣狭窄合并房间隔缺损患者(鲁腾巴赫综合征)与单纯二尖瓣狭窄患者相比症状明显较轻等观察结果,已经研发了几种房间隔分流装置(IASD),旨在通过建立向右心房的分流来减轻左心房压力。较小规模的研究发现,IASD可降低运动时的左心室充盈压,并在主观和客观上提高患者的功能状态,且报道的并发症发生率较低。这些装置正在接受进一步研究,可能会成为治疗HFpEF患者的一种新范例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f80e/9383341/37854aecabec/ijhf-4-12-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f80e/9383341/37854aecabec/ijhf-4-12-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f80e/9383341/37854aecabec/ijhf-4-12-g001.jpg

相似文献

1
Transcatheter Implantation of Interatrial Shunt Devices to Lower Left Atrial Pressure in Heart Failure.经导管植入房间隔分流装置以降低心力衰竭患者的左心房压力
Int J Heart Fail. 2022 Jan 19;4(1):12-23. doi: 10.36628/ijhf.2021.0038. eCollection 2022 Jan.
2
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I).用于治疗心力衰竭的经导管房间隔分流装置:降低心力衰竭患者升高的左心房压力的随机试验(REDUCE LAP-HF I)的原理与设计
Circ Heart Fail. 2016 Jul;9(7). doi: 10.1161/CIRCHEARTFAILURE.116.003025.
3
A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial.经导管左心室内分流装置治疗射血分数保留的心力衰竭(REDUCE LAP-HF):一项多中心、开放标签、单臂、1 期试验。
Lancet. 2016 Mar 26;387(10025):1298-304. doi: 10.1016/S0140-6736(16)00704-2.
4
Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction.房间隔分流装置对射血分数保留心力衰竭患者生存和心力衰竭住院的影响。
ESC Heart Fail. 2019 Feb;6(1):62-69. doi: 10.1002/ehf2.12350. Epub 2018 Oct 11.
5
Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF) Trial.心力衰竭患者降低升高的左心房压力(Reduce LAP-HF)试验的原理与设计
J Card Fail. 2015 Jul;21(7):594-600. doi: 10.1016/j.cardfail.2015.05.008. Epub 2015 Jun 6.
6
Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure.经导管治疗射血分数保留或轻度降低的心衰:使用新型房间隔植入物降低左心房压力。
Eur J Heart Fail. 2014 Jul;16(7):796-801. doi: 10.1002/ejhf.111. Epub 2014 Jun 24.
7
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial.经导管房间隔分流装置治疗射血分数保留的心力衰竭(REDUCE LAP-HF I [降低心力衰竭患者左心房压力]):一项 2 期、随机、假手术对照试验。
Circulation. 2018 Jan 23;137(4):364-375. doi: 10.1161/CIRCULATIONAHA.117.032094. Epub 2017 Nov 15.
8
One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction.经导管插入房间隔分流装置治疗射血分数保留的心力衰竭的一年结局
Circ Heart Fail. 2016 Dec;9(12):e003662. doi: 10.1161/CIRCHEARTFAILURE.116.003662.
9
Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction.基于器械的经皮治疗以减轻射血分数保留的心力衰竭患者的左心房压力。
Heart Fail Rev. 2023 Mar;28(2):315-330. doi: 10.1007/s10741-022-10280-4. Epub 2022 Nov 19.
10
Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review.射血分数保留的心力衰竭的新型经皮介入治疗:综合评价。
Heart Fail Rev. 2019 Sep;24(5):793-803. doi: 10.1007/s10741-019-09787-0.

引用本文的文献

1
Novel device therapies in heart failure: focus on patient selection.心力衰竭的新型器械治疗:关注患者选择。
Front Cardiovasc Med. 2025 Feb 25;12:1419873. doi: 10.3389/fcvm.2025.1419873. eCollection 2025.
2
Interventional therapies for chronic heart failure: An overview of recent developments.慢性心力衰竭的介入治疗:近期进展概述
ESC Heart Fail. 2025 Apr;12(2):1081-1094. doi: 10.1002/ehf2.15114. Epub 2024 Nov 11.
3
Fenestrated GORE® CARDIOFORM ASD occluder for transcatheter atrial septal defect closure in a geriatric patient.

本文引用的文献

1
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
2
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
3
Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction.
用于老年患者经导管房间隔缺损封堵术的带孔GORE® CARDIOFORM房间隔缺损封堵器
J Cardiol Cases. 2024 Apr 26;30(2):31-34. doi: 10.1016/j.jccase.2024.04.001. eCollection 2024 Aug.
4
Interatrial Shunt Devices.房间隔分流装置
Heart Fail Clin. 2024 Jan;20(1):61-69. doi: 10.1016/j.hfc.2023.05.003. Epub 2023 Jul 4.
5
Role of cardiac imaging in management of heart failure.心脏影像学在心力衰竭管理中的作用。
Korean J Intern Med. 2023 Sep;38(5):607-619. doi: 10.3904/kjim.2023.262. Epub 2023 Aug 29.
心力衰竭伴射血分数保留患者运动时心率和每搏量反应的决定因素及后果。
Eur J Heart Fail. 2021 May;23(5):754-764. doi: 10.1002/ejhf.2146. Epub 2021 Mar 22.
4
One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study.首例在有症状心力衰竭患者中左心房分流的心房血流调节剂的人体研究的一年结果:PRELIEVE 研究。
Eur J Heart Fail. 2021 May;23(5):800-810. doi: 10.1002/ejhf.2119. Epub 2021 Mar 5.
5
Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II).经导管房间隔分流装置治疗心力衰竭:心力衰竭患者降低左心房压力的关键性随机试验的原理和设计 II(REDUCE LAP-HF II)。
Am Heart J. 2020 Aug;226:222-231. doi: 10.1016/j.ahj.2019.10.015. Epub 2019 Nov 11.
6
Percutaneous Atriotomy for Levoatrial-to-Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience.经皮房间隔切开术用于治疗症状性心力衰竭患者的左心房至冠状窦分流:首例人体经验。
JACC Cardiovasc Interv. 2020 May 25;13(10):1236-1247. doi: 10.1016/j.jcin.2020.02.022.
7
Medical Therapies for Heart Failure With Preserved Ejection Fraction.射血分数保留的心力衰竭的医学治疗方法。
Hypertension. 2020 Jan;75(1):23-32. doi: 10.1161/HYPERTENSIONAHA.119.14057. Epub 2019 Dec 2.
8
Interatrial shunt with the second-generation V-Wave system for patients with advanced chronic heart failure.第二代V波系统用于晚期慢性心力衰竭患者的房间隔分流术
EuroIntervention. 2020 Mar 20;15(16):1426-1428. doi: 10.4244/EIJ-D-19-00291.
9
The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction.AFR-PRELIEVE 试验:一项前瞻性、非随机、初步研究,旨在评估在射血分数保留或降低的心力衰竭患者中使用心房流量调节器(AFR)的效果。
EuroIntervention. 2019 Aug 29;15(5):403-410. doi: 10.4244/EIJ-D-19-00342.
10
Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction.射血分数保留的心力衰竭患者运动能力的中心和外周决定因素。
JACC Heart Fail. 2019 Apr;7(4):321-332. doi: 10.1016/j.jchf.2019.01.006. Epub 2019 Mar 6.